Printer Friendly

BIOMIRA INC. ANNOUNCES START OF U.S. PHASE II BREAST CANCER CLINICAL TRIAL USING THERATOPE(R) STnKLH

 EDMONTON, Alberta, Oct. 1 /PRNewswire/ -- Biomira Inc. (NASDAQ: BIOMF; Toronto, Montreal: BRA) today reported that the U.S. Food & Drug Administration (FDA) has reviewed Biomira's Investigational New Drug Application (IND) for a Phase II Clinical Trial using THERATOPE(R) STn-KLH (Sialyl-Tn), allowing the company to begin its first U.S. clinical trial. The single-center dose range study will include 45 patients with minimal metastatic breast cancer. Parameters of the study will be released by the participating center, the University of Southern California/Norris Comprehensive Cancer Center on Oct. 4, 1993.
 "The initiation of our first Phase II clinical trial in the United States is a milestone for Biomira," said Alex McPherson, M.D., Ph.D. "We hope this trial will provide valuable information in helping treat breast cancer; a disease affecting one out of every nine women in America. The affiliation with this outstanding cancer center adds to our belief that this will be a very important trial," McPherson concluded.
 Phase I safety studies, as reported earlier, indicated that THERATOPE(R) is safe for further studies in humans. Phase II clinical trials testing THERATOPE(R) STn-KLH in the treatment of breast, colon, pancreatic, and ovarian cancer are ongoing in Canada and the United Kingdom; Phase II studies will continue to report on safety data, as well as therapeutic response and patient acceptability. Preliminary observations on the Phase II data will be reported at a scientific presentation in San Francisco on Oct. 2, 1993.
 The company is also developing monoclonal antibody-based products for cancer imaging. Patient enrollment has been completed for German Phase I/II clinical trials of Tru-Scint(R) SQ(TM) for squamous cell carcinomas of the head and neck. Canadian trials for Tru-Scint(R) SQ(TM) also are nearing completion. Biomira is also close to completing patient enrollment in the Canadian breast cancer trial of Tru-Scint(R) AD(TM). Other Canadian and German trials continue.
 Biomira Inc. is a Canadian biotechnology company dedicated to the development of products to diagnose and treat cancer. It is refining its technology in the areas of active specific immunotherapy, radioimmunoimaging and radioimmunotherapy. Biomira holds a significant interest in HealthVISION Corp. of Vancouver, and ADI Diagnostics Inc. of Toronto. ADI manufactures and distributes Biomira's TRUQUANT(R) cancer diagnostic kits.
 -0- 10/1/93
 /CONTACT: Jane Jack, Investor Relations Coordinator, Biomira Inc., c/o Fairmont Hotel - San Francisco, 415-772-5000; or Mark J. Brand or Kimberley A. Kraemer, Pondel Parsons & Wilkinson, 310-207-9300/
 (BIOMF)


CO: Biomira Inc. ST: Alberta IN: MTC SU:

MF-LS -- LA034 -- 8012 10/01/93 19:06 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 1, 1993
Words:424
Previous Article:RED LINE CONSTRUCTION COSTS EXPECTED TO BE UNDER BUDGET BY $30 MILLION TO $40 MILLION
Next Article:SPELLING PREMIERE NETWORK
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters